Dr. Marschall S. Runge Elected to Lilly Board of Directors

          Dr. Marschall S. Runge Elected to Lilly Board of Directors

PR Newswire

INDIANAPOLIS, Aug. 28, 2013

INDIANAPOLIS, Aug. 28, 2013 /PRNewswire/ -- The Board of Directors of Eli
Lilly and Company (NYSE: LLY) has elected Marschall S. Runge, M.D., Ph.D., as
a new member, effective September 1, 2013. Dr. Runge, 59, is the Executive
Dean for the School of Medicine at the University of North Carolina at Chapel
Hill (UNC). As a member of Lilly's board, Dr. Runge will serve on the Science
and Technology Committee and the Public Policy and Compliance Committee.

"I am very pleased to welcome Marschall Runge to the Lilly board," said John
Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "Dr.
Runge brings to the Lilly board a broad background in health care, with
extensive experience as a practicing physician, clinical researcher, and dean
of a major academic medical institution. His appreciation of the importance of
scientific research, coupled with his first-hand experience in patient care,
will help Lilly deliver on its commitment to discover and develop innovative
medicines that make a difference for patients in need."

In his role as Executive Dean for the UNC School of Medicine, Dr. Runge
provides overall academic and clinical leadership for the School of Medicine
and the UNC Health Care System. In addition to being the Chair of the
Department of Medicine, Dr. Runge is also Principal Investigator and Director
of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute
at UNC-Chapel Hill, where he has financial, human resource and strategic
oversight responsibilities for the program. The NC TraCS Institute is one of
60 medical research institutions working together as part of a national
consortium to improve the way biomedical research is conducted across the
country and to reduce the time it takes for laboratory discoveries to become
new treatments for patients.

An honors graduate of Vanderbilt University with a B.A. in Biology and a Ph.D.
in molecular biology, Dr. Runge earned his M.D. from the Johns Hopkins School
of Medicine, where he was an intern and resident in internal medicine. He then
completed a cardiology fellowship at Harvard's Massachusetts General Hospital
and was a faculty member there prior to moving to Emory University as an
Associate Professor of Medicine in 1989. Before joining the UNC faculty in
2000, Dr. Runge held the John Sealy Distinguished Centennial Chair in Internal
Medicine and was Director of the Division of Cardiology and the Sealy Center
for Molecular Cardiology at the University of Texas Medical Branch at
Galveston.

In addition to serving as a member of the Experimental Cardiovascular Sciences
Study Section of the National Institutes of Health, Dr. Runge also has
published over 150 peer-reviewed manuscripts and is a renowned leader in
vascular biology.

About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers--
through medicines and information-- for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com. C-LLY

Refer to: (317) 433-9899 – Edward Sagebiel

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)



SOURCE Eli Lilly and Company

Website: http://www.lilly.com
 
Press spacebar to pause and continue. Press esc to stop.